FIGURE 5 Recommendation: NAC could be considered for patients with NCF bronchiectasis who experience 2 exacerbations per year
BPC-157 is not a controlled substance and is unlikely to be detected on a standard workplace drug test, which typically screens for common drugs of abuse
"Most of the people we're seeing aren't necessarily high performing or recreational athletes
They are urging additional research to better understand the effects of the drugs and ensure patients get the best possible outcomes
13 C-NMR (100 MHz, CDCl 3 ): 196.0, 167.6, 148.7, 145.7, 132.3, 130.5, 130.3, 128.8, 127.6, 123.9, 120.9, 120.0, 118.8, 109.5, 108.2, 50.3, 48.2, 41.4, 32.2, 29.0, 27.5 ppm
Coverage for Wegovy varies and generally requires prior authorization